206 related articles for article (PubMed ID: 34158306)
1. Perspectives of people with inherited retinal diseases on ocular gene therapy in Australia: protocol for a national survey.
Mack HG; Chen FK; Grigg J; Jamieson R; De Roach J; O'Hare F; Britten-Jones AC; McGuinness M; Tindill N; Ayton L;
BMJ Open; 2021 Jun; 11(6):e048361. PubMed ID: 34158306
[TBL] [Abstract][Full Text] [Related]
2. An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials.
Chiu W; Lin TY; Chang YC; Isahwan-Ahmad Mulyadi Lai H; Lin SC; Ma C; Yarmishyn AA; Lin SC; Chang KJ; Chou YB; Hsu CC; Lin TC; Chen SJ; Chien Y; Yang YP; Hwang DK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926102
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy in Hereditary Retinal Dystrophies: The Usefulness of Diagnostic Tools in Candidate Patient Selections.
Malvasi M; Casillo L; Avogaro F; Abbouda A; Vingolo EM
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762059
[TBL] [Abstract][Full Text] [Related]
4. Voretigene neparvovec-rzyl for treatment of
Ciulla TA; Hussain RM; Berrocal AM; Nagiel A
Expert Opin Biol Ther; 2020 Jun; 20(6):565-578. PubMed ID: 32149547
[No Abstract] [Full Text] [Related]
5. Gene therapy for inherited retinal diseases: progress and possibilities.
Hu ML; Edwards TL; O'Hare F; Hickey DG; Wang JH; Liu Z; Ayton LN
Clin Exp Optom; 2021 May; 104(4):444-454. PubMed ID: 33689657
[TBL] [Abstract][Full Text] [Related]
6. [Inherited retinal dystrophy: first results of RPE65 gene replacement therapy in Russia].
Kadyshev VV; Zolnikova IV; Khalanskaya OV; Stepanova AA; Kutsev SI
Vestn Oftalmol; 2022; 138(4):48-57. PubMed ID: 36004591
[TBL] [Abstract][Full Text] [Related]
7. Current Management of Patients with RPE65 Mutation-Associated Inherited Retinal Degenerations in Europe: Results of a Multinational Survey by the European Vision Institute Clinical Research Network.
Lorenz B; Tavares J; van den Born LI; Marques JP; Scholl HPN;
Ophthalmic Res; 2021; 64(5):740-753. PubMed ID: 33684911
[TBL] [Abstract][Full Text] [Related]
8. Subretinal Injection of Voretigene Neparvovec-rzyl in a Patient With RPE65-Associated Leber's Congenital Amaurosis.
Hussain RM; Tran KD; Maguire AM; Berrocal AM
Ophthalmic Surg Lasers Imaging Retina; 2019 Oct; 50(10):661-663. PubMed ID: 31671202
[TBL] [Abstract][Full Text] [Related]
9. RPE65-associated inherited retinal diseases: consensus recommendations for eligibility to gene therapy.
Sodi A; Banfi S; Testa F; Della Corte M; Passerini I; Pelo E; Rossi S; Simonelli F;
Orphanet J Rare Dis; 2021 Jun; 16(1):257. PubMed ID: 34088339
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease.
Johnson S; Buessing M; O'Connell T; Pitluck S; Ciulla TA
JAMA Ophthalmol; 2019 Oct; 137(10):1115-1123. PubMed ID: 31318398
[TBL] [Abstract][Full Text] [Related]
11. The first gene therapy for
Ferraz Sallum JM; Godoy J; Kondo A; Kutner JM; Vasconcelos H; Maia A
Ophthalmic Genet; 2022 Aug; 43(4):550-554. PubMed ID: 35416119
[TBL] [Abstract][Full Text] [Related]
12. An optometrist's guide to the top candidate inherited retinal diseases for gene therapy.
O'Hare F; Edwards TL; Hu ML; Hickey DG; Zhang AC; Wang JH; Liu Z; Ayton LN
Clin Exp Optom; 2021 May; 104(4):431-443. PubMed ID: 33689629
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for RPE65-related retinal disease.
Miraldi Utz V; Coussa RG; Antaki F; Traboulsi EI
Ophthalmic Genet; 2018 Dec; 39(6):671-677. PubMed ID: 30335549
[TBL] [Abstract][Full Text] [Related]
14. Utility of In Vitro Mutagenesis of RPE65 Protein for Verification of Mutational Pathogenicity Before Gene Therapy.
Yang U; Gentleman S; Gai X; Gorin MB; Borchert MS; Lee TC; Villanueva A; Koenekoop R; Maguire AM; Bennett J; Redmond TM; Nagiel A
JAMA Ophthalmol; 2019 Dec; 137(12):1381-1388. PubMed ID: 31580392
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostics and management of patients with inherited retinal diseases in Germany : Results of a nationwide survey of university and non-university eye departments and specialized practices].
Künzel SH; Mahren E; Morr M; Holz FG; Lorenz B;
Ophthalmologie; 2023 Nov; 120(11):1127-1137. PubMed ID: 37582888
[TBL] [Abstract][Full Text] [Related]
16. Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis.
Gange WS; Sisk RA; Besirli CG; Lee TC; Havunjian M; Schwartz H; Borchert M; Sengillo JD; Mendoza C; Berrocal AM; Nagiel A
Ophthalmol Retina; 2022 Jan; 6(1):58-64. PubMed ID: 33838313
[TBL] [Abstract][Full Text] [Related]
17. [Gene therapy treatment based on an ophthalmic indication in hereditary retinal dystrophy caused by RPE65 biallelic gene mutation.].
Vizvári E; Smeller L; Jánossy Á; Lőrincz M; Janáky M; Tóth-Molnár E
Orv Hetil; 2022 Nov; 163(48):1923-1931. PubMed ID: 36436058
[TBL] [Abstract][Full Text] [Related]
18. Survey of perspectives of people with inherited retinal diseases on ocular gene therapy in Australia.
Mack HG; Britten-Jones AC; McGuinness MB; Chen FK; Grigg JR; Jamieson RV; Edwards TL; De Roach J; O'Hare F; Martin KR; Ayton LN
Gene Ther; 2023 Apr; 30(3-4):336-346. PubMed ID: 36183012
[TBL] [Abstract][Full Text] [Related]
19. Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration.
Fuller-Carter PI; Basiri H; Harvey AR; Carvalho LS
BioDrugs; 2020 Dec; 34(6):763-781. PubMed ID: 33136237
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
